Open in PodwiseOpen

Podcast cover

BioSpace · Business

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

51%: The Untapped Market

RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

Investing in AI: Benefits, Regulatory Challenges

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More

Steady But Slow: Future Outlook for Investment

Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More

Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More

How AI Could Ease Tension in Clinical Trials

BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More

BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day

AI Return on Investment: Just Because We Can, Should We?

Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval

Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024

AI Promises: Funding Data Literacy and Reality First

BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement

Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

Page 10

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise